GSK has opened a £56 million state-of-the-art manufacturing facility, creating 150 new jobs in the UK, in response to demand for GSK’s portfolio of respiratory medicines delivered by the innovative Ellipta inhaler.
The 4500m2 facility is the latest expansion for Ellipta manufacturing at Ware, with investment totalling over £100 million over the past five years. It is expected to nearly double production of Ellipta inhalers at Ware to at least 37 million per year by 2017, 95% of which will be exported.
Since 2013, over 400 additional roles will have been created at the manufacturing site in Ware, bringing staff numbers to more than 1200.
Sir Andrew Witty, CEO, GSK said: “This new facility demonstrates our commitment to manufacturing in the UK which continues to be a very positive environment for life sciences investment. We have been leaders in respiratory since the 1960s when we first began making inhalers for the treatment of respiratory diseases in Ware and it continues to be a critically important site for us, both in terms of researching and developing innovative new inhaler technology, and as a world-leading manufacturing hub.
“We currently export Ellipta inhalers from Ware to over 74 countries and the new facility opened today will increase capacity to meet growing demand for our new portfolio of respiratory medicines worldwide.”
Life Sciences Minister George Freeman MP added: “This £56 million investment by GSK is fantastic news for Ware and the UK’s thriving life sciences industry. As well as driving growth and creating 150 new jobs, this expansion of GSK’s medicines manufacturing facility in Ware is a strong endorsement of the UK’s leadership in manufacturing and respiratory medicine.”
Image shows GSK House and not the new facility in Ware.